These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 4000901)
1. Research in the Division of Toxicology. The importance of reactive intermediates of drug biotransformation in drug toxicity. Mulder GJ Pharm Weekbl Sci; 1985 Apr; 7(2):67-70. PubMed ID: 4000901 [TBL] [Abstract][Full Text] [Related]
3. Sex differences in drug conjugation and their consequences for drug toxicity. Sulfation, glucuronidation and glutathione conjugation. Mulder GJ Chem Biol Interact; 1986 Jan; 57(1):1-15. PubMed ID: 3081267 [No Abstract] [Full Text] [Related]
4. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. Erve JC Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):923-46. PubMed ID: 17125409 [TBL] [Abstract][Full Text] [Related]
5. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates. Orhan H; Vermeulen NP Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525 [TBL] [Abstract][Full Text] [Related]
6. Reactive metabolites as key intermediates in pharmacologic and toxicologic responses: examples from chemical carcinogenesis. Miller EC; Miller JA Adv Exp Med Biol; 1981; 136 Pt A():1-21. PubMed ID: 7344452 [No Abstract] [Full Text] [Related]
7. Effect of diet on the metabolism and toxicology of drugs. Ioannides C; Parke DV J Hum Nutr; 1979 Oct; 33(5):357-66. PubMed ID: 115915 [TBL] [Abstract][Full Text] [Related]
8. Measurement of urinary metabolites of xenobiotics as a non-invasive technique in toxicology. Breimer DD Arch Toxicol Suppl; 1982; 5():162-78. PubMed ID: 6954894 [TBL] [Abstract][Full Text] [Related]
9. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Masubuchi N; Makino C; Murayama N Chem Res Toxicol; 2007 Mar; 20(3):455-64. PubMed ID: 17309281 [TBL] [Abstract][Full Text] [Related]
11. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Baillie TA Chem Res Toxicol; 2006 Jul; 19(7):889-93. PubMed ID: 16841955 [TBL] [Abstract][Full Text] [Related]
13. Many drugs and phytochemicals can be activated to biological reactive intermediates. Johnson WW Curr Drug Metab; 2008 May; 9(4):344-51. PubMed ID: 18473753 [TBL] [Abstract][Full Text] [Related]
14. [Clinical pharmacologic aspects of cytochrome P-450 dependent biotransformation of drugs]. Ackermann E Pharmazie; 1978 Jul; 33(7):400-6. PubMed ID: 364493 [No Abstract] [Full Text] [Related]
15. Clinical pharmacological aspects of drug toxicity testing. Ackermann E Pol J Pharmacol Pharm; 1980; 32(2):237-41. PubMed ID: 7454628 [TBL] [Abstract][Full Text] [Related]
16. Research in the Division of Pharmacology. Breimer DD Pharm Weekbl Sci; 1985 Apr; 7(2):63-6. PubMed ID: 4000900 [TBL] [Abstract][Full Text] [Related]
17. Nonlinear pharmacokinetics relative to toxicity and use of toxicological data. Ramsey JC Drug Metab Rev; 1982; 13(5):779-97. PubMed ID: 6754308 [No Abstract] [Full Text] [Related]
18. Active metabolites in toxicology: the role of cytochrome P-448 and flavoprotein oxidases. Parke DV; Ioannides C Arch Toxicol Suppl; 1984; 7():183-92. PubMed ID: 6595982 [TBL] [Abstract][Full Text] [Related]
19. Phase II enzymes and bioactivation. Hinson JA; Forkert PG Can J Physiol Pharmacol; 1995 Oct; 73(10):1407-13. PubMed ID: 8748931 [TBL] [Abstract][Full Text] [Related]
20. Sources of uncertainty in pharmacokinetic prediction. Braun WH; Waechter JM J Anim Sci; 1983 Jan; 56(1):235-43. PubMed ID: 6337985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]